© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
2,3-Dimercapto-1-propanol, known to many as British anti-Lewisite or BAL, tells a fascinating story about necessity and ingenuity in wartime Britain. Chemists at Oxford University saw the havoc chemical weapons could unleash during World War II, especially arsenic-based agents. Military medics needed a way to counteract poisoning, and so they turned to sulfur chemistry, rooting through compounds that could pull heavy metals out of biological systems. Within this context, BAL was developed, earning its original name as a direct reference to its role against Lewisite, an arsenic-containing gas. The earliest uses appeared almost out of desperation, treating poisoned soldiers, but the story carried on. Instead of fading into a postwar chemical footnote, BAL kept showing up in medicine and research, not just as an antidote but also as a tool for studying heavy metal burdens in humans. Knowledge about heavy metal poisoning expanded rapidly, and so did the applications and forms of 2,3-dimercapto-1-propanol.
Diving into the present, this compound straddles two worlds. In the lab, chemists see BAL as a dithiol, a molecule that binds to metals with an impressive eagerness, especially soft metals like arsenic, mercury, or lead. In clinical medicine, toxicologists administer formulations based on this chemistry when someone comes in with heavy metal poisoning. The versatility stretches even further. Scientists have been attentive to its capabilities as a chelating agent, so the compound impacts environmental monitoring and industrial hygiene, areas that touch all of us whether or not we see the direct connection. You won’t find BAL in consumer products or household cabinets, but teams working close to hazardous metals know its role and keep it on hand.
Anyone handling 2,3-dimercapto-1-propanol can spot it by its pungent, sulfurous odor. The compound is an oily, slightly viscous liquid with a faint amber tint. Chemically, those twin thiol (–SH) groups give it a strong affinity for metal ions, forming stable cyclic complexes in the process. With a molecular formula of C3H8O(SH)2, and a molecular weight of around 124 grams per mole, this is a small molecule but it hardly behaves inconspicuously. It shows moderate solubility in water with higher solubility in organic solvents, thanks to the interplay of its hydroxyl and mercapto functionalities. These groups not only define its core reactivity but are crucial to every technical and therapeutic use. Volatility remains low, meaning it sticks with whatever solution you put it in unless heat breaks it down or it reacts with another agent. With enough exposure to air, the compound can oxidize, transforming those thiols into disulfides, changing its properties and effectiveness.
In any setting that trades in precise dosing—a hospital pharmacy, a chemical supplier, or an industrial hygiene lab—clarity around BAL’s purity and composition matters. Documentation usually details purity above 95%, with water and related sulfur compounds as the main impurities. Labeling practices require clear hazard communication because contact with the compound can irritate skin and mucous membranes, and the odor reminds even the most distracted technician to treat the bottle respectfully. Transport and storage guidelines tend to advise dark, tightly sealed containers, keeping moisture and oxygen to a minimum so the active thiol groups don’t degrade. This is not a casual-use compound. Even labeling conventions for clinical uses, where 2,3-dimercapto-1-propanol is mixed with a suitable diluent before injection, emphasize the need to dilute and administer under strict supervision, in part because of possible adverse effects.
Synthesizing 2,3-dimercapto-1-propanol isn’t a trivial task, but chemists, given the tools of organic synthesis, approach the process in a logical way. Starting from 1,2-dibromopropanol or glycerol, they introduce thiol groups using reagents like sodium hydrogen sulfide. This is a textbook nucleophilic substitution, with bromine atoms replaced by sulfur. Filtering, neutralization, and distillation follow, all under controlled temperature to avoid decomposition. Each of these steps not only brings the right product but minimizes side reactions, which are more likely than most students believe since thiol chemistry can wander into unpredictable territory if pH or temperature slides out of bounds. Large-scale production keeps environmental impacts in mind, since organosulfur chemistry, done thoughtlessly, produces nasty-smelling byproducts.
In the hands of innovative scientists, BAL acts as a launching pad for developing new chelating agents. Its two mercapto groups give it a strong capacity for metal capture, but chemists experiment with protecting groups, oxidation to form disulfides, and coupling to other pharmaceutical units, seeking molecules with different solubilities or lower toxicity. In research, scholars have grafted BAL derivatives onto various scaffolds to tailer kinetics or specificity. Michael addition reactions, direct alkylations, or esterifications introduce subtle but impactful changes, testing whether such variants improve clinical outcomes or analytic selectivity. Modifying the chemical essentially opens doors— some to better antidotes, others to more effective sensors for environmental toxins.
People in clinical toxicology circles often call 2,3-dimercapto-1-propanol “British anti-Lewisite,” honoring its origins. In conversations among organic chemists, it’s just BAL or sometimes dimercaprol. The diversity of terminology in published literature can confuse newcomers; a quick scan of Medline, PubChem, or the Haz-Map database reveals the maze of names: Dimercaprol, 2,3-dimercaptopropanol, and, less commonly, HSCH2CH(OH)CH2SH. Some advanced chelating agents in modern use trace their architecture to BAL’s sulfur backbone, borrowing and modifying the base structure while adopting new trade names in the pharmaceutical world.
Every technician or clinician who touches this compound internalizes its hazards. It can easily irritate skin, cause nausea if inhaled, or feel caustic in the eyes and nose. Absorption through skin should always be prevented by standard gloves and fume hoods, not just for personal comfort but for real protection against cumulative low-dose effects. Clinics and hospitals run regular drills for diluting and administering BAL, recognizing that dosing must be calculated precisely; overdosing can trigger hypertension, vomiting, or even neurologic reactions. When I started in a clinical lab, rigorous training meant learning contamination controls and waste handling, as thiols are notorious for lingering odors and difficult-to-remove residues. Procedures stress containment, with spill kits and emergency showers always close, and all waste heading to specialized disposal streams. These are not just bureaucratic hurdles; the risk is real and long-lasting, particularly for repeated low-level exposure.
If physicians see a case of arsenic, mercury, or gold poisoning, BAL sits at the center of treatment protocols. Its speed of action and proven ability to bind metals have saved countless lives in acute emergencies, from industry accidents to rural villages affected by mining runoffs. It expands beyond clinical medicine, popping up in environmental science laboratories that routinely measure toxin levels in polluted water, soil, or biological samples. Industrial safety experts train with dimercaprol to understand best practices for remediation and exposure response. For those who dig into medical history or toxicology, the influence of BAL spreads further, affecting how scientists have conceptualized and tested chelation therapies for decades. Despite newer chelators entering clinics, BAL remains a viable fallback in cases where allergies or sensitivities restrict the use of modern agents.
Scientific curiosity keeps BAL near the front lines of toxicology research. The original molecule prompted researchers to look for analogues with reduced side effects, greater specificity, and improved pharmacokinetics. Ongoing studies pivot towards modifying the sulfur core, introducing bulkier groups to slow absorption or tailor the distribution in the body. Grant proposals routinely cite BAL as the chemical backbone to build new chelating tools, especially for contaminants that resist treatment by classic agents. It’s tempting to see BAL as an old remedy, but its chemical reactivity keeps it relevant wherever challenging poisons emerge. Researchers interested in mechanistic toxicology use dimercaprol to map out how metals interact with cellular proteins, shining a light on broader questions about how pollutants cause harm.
The paradox of using a toxic chemical to treat toxic exposures runs through every study of dimercaprol. Over the decades, animal studies and clinical reports have tracked everything from mild side effects like headache and nausea to more worrisome phenomona like high blood pressure, hemolysis, or allergic reactions. Modern toxicologists don’t just document acute effects—they run longitudinal studies, asking whether cumulative exposure leaves subtle long-term health consequences. Adverse reactions appear dose-dependent; no margin for error exists in accidentally giving too much or prolonging therapy beyond the minimal effective duration. As with many medicinal agents developed in a crisis era, researchers learned safety the hard way—through close observation of patients under controlled and sometimes desperate circumstances. Clinical guidelines keep evolving, incorporating new findings about biomarkers of harm, genetic susceptibility to side effects, and best practices for treating subpopulations like children and pregnant women.
Though BAL’s origin lies in an era overshadowed by wars and crude chemical weapons, its story is far from complete. Environmental chemists are now exploring its use in sensor technologies for detecting mercury and arsenic, leveraging its affinity for metals in fieldwork and remediation. Advances in medicinal chemistry promise new hybrid molecules, with the same chelating core but tuned for greater safety and more targeted metal capture. Ongoing concerns about industrial pollution and the legacy of heavy metals in soil and water mean that BAL and its analogues have a future role in both medicine and environmental cleanup. Research grows ever more sophisticated, using high-throughput screens to search for next-generation agents, all rooted in lessons learned from the successes—and occasional failures—of BAL. Where there are new insights into heavy metal biochemistry, the influence of 2,3-dimercapto-1-propanol stands out as a bridge between urgent history and innovative science.
2,3-Dimercapto-1-propanol sounds like a mouthful, but most folks in medicine and toxicology know it better as British Anti-Lewisite, or BAL. This compound first appeared as a secret weapon during World War II, designed to counteract the deadly effects of lewisite, a chemical warfare agent. That backstory isn’t just trivia; it explains why this stuff still sits on pharmacy shelves worldwide.
Poisoning cases related to heavy metals put pressure on healthcare systems and families every year. 2,3-Dimercapto-1-propanol helps neutralize some of the nastiest offenders—arsenic, mercury, and lead. The compound binds to these metals in the body, helping the kidneys flush them out. By itself, the body struggles to get rid of these toxins, and symptoms get ugly. Children exposed to lead—often from old paint dust or contaminated water—sometimes face developmental delays and lifelong health hurdles. A real-world solution comes in the form of therapies like BAL.
Ask anyone who’s seen a severe case of acute metal poisoning: Success depends on working fast and using the right antidote. BAL isn’t always the first line for every type of poisoning, but for certain cases, it turns a deadly scenario into a manageable one. Take arsenic poisoning, which turns up globally from tainted water or intentional tampering. BAL's two –SH (thiol) groups act almost like magnets for heavy metals, grabbing and holding tight so the body can expel them. A child who swallowed an old thermometric bulb, or a worker with accidental mercury exposure, has a fighting chance thanks to 2,3-Dimercapto-1-propanol.
Modern medicine tracks plenty of alternatives for heavy metal chelation: DMSA and EDTA fill gaps BAL can’t cover. But in developing countries and areas hit by sudden poisonings, BAL offers a critical and accessible solution. Hospitals dealing with limited resources depend on medicines that are tried, tested, and effective.
No medicine comes without trade-offs. Some patients react to BAL with nausea, high blood pressure, or pain at the injection site. When possible, doctors check allergies ahead of time and watch for complications. The truth: in life-or-death situations, these risks pale against the dangers of heavy metal poisoning itself. Healthcare workers learn to use BAL as part of a toolkit, and not as a universal fix.
Some of the oldest cities in the world still have pipes and paints rooted in the past, leeching lead and other toxins. Industries dump mercury and arsenic into the ecosystem. Real solutions demand more than just antidotes. Public health teams push for cleaner water, safer homes, and strict regulations on industrial waste. These preventive steps shrink the number of cases needing BAL in the first place.
Telling the story of 2,3-Dimercapto-1-propanol isn’t just about chemistry. It’s about making sure people, especially the most vulnerable, have a shot at recovery. History, science, and public health come together here. BAL’s legacy proves that fast action, paired with smart policy, saves lives.
People have called 2,3-Dimercapto-1-propanol many names, but “British Anti-Lewisite” tells you plenty about its roots. This compound showed up during World War II, developed to treat people exposed to lewisite, a chemical weapon. Since then, the medical world has turned to it as a key player in treating certain types of heavy metal poisoning.
The science behind this compound isn’t all that complicated. Think of heavy metals in the body, like arsenic or mercury, as uninvited guests causing trouble at a party. 2,3-Dimercapto-1-propanol latches onto those toxic metals, like bouncers escorting troublemakers out the door, making it possible for the body to flush them out through urine. Doctors have leaned on this stuff when speed matters—a patient exposed to too much mercury, for example, needs it out yesterday.
No one should reach for the medicine cabinet and start using 2,3-Dimercapto-1-propanol without medical advice. It’s not like popping a vitamin. Research and long-term clinical use show that it helps clear dangerous heavy metals, but it does not come risk-free. People have experienced side effects. Some get high blood pressure, racing heart, headaches, or nausea. The more that’s given, the bigger the chance for harm. It can irritate tissues if not given properly, especially in children. Skin rashes and allergic reactions have popped up, and people with liver or kidney problems face added danger.
Doctors and toxicologists know all this because they have observed real cases. The World Health Organization and poison control experts agree that the compound can be life-saving, but only when the diagnosis is clear and the dose is right. Research has backed up its effectiveness for acute poisoning, like arsenic gas exposure or certain industrial accidents. But this isn’t a “detox” pill for people worried about vague symptoms.
Safety with this drug isn’t just about the molecule itself. It depends on knowledge and skill in medical settings. Trained staff, such as emergency doctors and clinical toxicologists, monitor vital signs, adjust doses, and look out for side effects. They weigh risks and benefits for each patient, knowing that heavy metals cause lasting harm but so does reckless treatment. The people most at risk—small children, the elderly, anyone with poor kidneys—need the closest attention.
Scientists have pushed to develop safer options, like oral chelators that may cause fewer problems. Still, 2,3-Dimercapto-1-propanol remains useful in emergencies, especially where other drugs won’t cut it. Physicians measure blood and urine levels of metals and stay up-to-date with research to balance urgency against risk.
There’s a lesson in this story. A drug with roots in wartime still saves lives in hospitals, but it works best in the right hands. Professional guidance, careful monitoring, and public awareness keep stiff medicine from turning toxic. Those facing threats from heavy metals—factory workers, children living near contaminated water, or anyone at risk—deserve access to lifesaving care rooted in expertise and evidence, not blind hope.
2,3-Dimercapto-1-propanol—usually called British anti-Lewisite or BAL—carries a heavy responsibility in medicine. Doctors rely on BAL for treating poisoning from heavy metals like arsenic, mercury, and lead. Since these poisons threaten lives, the stakes run high, and BAL sometimes comes with baggage.
I spent years working in clinical settings. Whenever BAL made it to a patient’s chart, staff prepared for side effects. The sense of urgency around these treatments meant nurses never left bedside monitoring to chance.
The most frequent complaints in my experience have been pain at the injection site. Patients wince, sometimes looking away as they brace for the sting. One patient described it like “fire under the skin,” even days after starting.
Other reactions show up all over the body. Upset stomach, nausea, vomiting—sometimes enough to cause dehydration. Taking care of kids exposed to lead, I watched families struggle as their children would retch and lose energy during the process.
High doses or fast infusions can bring on headaches, fever, and even a racing heart. I’ve watched patients shiver with chills. Sweating follows, sometimes drenching the sheets. Allergic reactions remain a real risk. Rash or swollen lips can stop the treatment entirely.
Not everyone gets just routine discomfort. Some people develop low blood pressure. I recall a patient who got dizzy, nearly fainting. The doctors moved quickly—lowering the infusion rate, bringing fluids, always staying sharp for more trouble.
Blood and urine tests sometimes show temporary changes after BAL treatment. These changes can look like anemia or liver strain. With mercury poisoning, some patients developed nerve symptoms—tingling or numbness in their feet. This underscores why close supervision counts.
Clinicians who handle BAL focus on careful dosing and steady monitoring. Slow infusion reduces the risk of shock or allergic reactions. Hydrating patients helps manage kidney strain and flush out toxins. Lab tests, sometimes twice a day, pick up trouble before it spirals.
Hospitals carrying this medicine keep resuscitation drugs and gear close at hand. Allergic reactions move fast, so being prepared isn’t negotiable. My colleagues double-checked every vial and calculated doses by weight—one mistake can cause harm.
Every treatment brings tough decisions. Doctors weigh the threat of heavy metal poisoning—brain damage, organ failure—against the known risks of BAL. For most life-threatening cases, the side effects feel like a price worth paying. Yet, for milder situations, alternative treatments sometimes get the nod.
Research into new chelating agents—medicines that grab and remove metals—moves forward every year. Oral agents and drugs with fewer side effects promise hope, especially for treating children.
Healthcare teams trust evidence. Laboratory and clinical data drive decisions, and that’s how patients get the best shot at recovery. Sharing stories and knowing what to expect helps families and staff stick together under pressure.
For me, watching patients pull through heavy metal poisoning thanks to BAL always brings relief. Yet, the memory of rough side effects sticks around—reminding everyone in the room that medicines, even lifesaving ones, come with real trade-offs.
Dealing with heavy metal poisoning can throw anyone’s life off balance. Lead, arsenic, mercury—these metals do more than just damage the body; they erode your sense of security. I’ve seen the stress a poisoning case brings to families, from frantic questions about treatment to real worry about long-term health. In these moments, 2,3-Dimercapto-1-propanol—called British anti-Lewisite or BAL—matters a lot. Knowing how to use it changes the course of an emergency.
Most people picture medicine as a pill or a syrup. That’s rarely the case for chelation therapies like BAL. This drug almost always comes as an oily liquid inside a glass ampule. Nurses and doctors draw up the dose, then inject it deep into the muscles, usually the glutes or thigh. Anyone who’s gotten a shot knows it’s not a small deal, but muscle injection gets the BAL into the bloodstream quicker, compared to swallowing a tablet that stomach acids might break down.
Deciding how much to give isn’t just math—it’s about watching a person’s reaction every hour. Children and adults get different doses, often split up three or four times a day. Doctors check symptoms and bloodwork, adjusting the plan if the patient develops side effects like high blood pressure, nausea, or pain at the injection site. My own relatives with lead exposure needed blood tests every few hours to make sure the drugs didn’t cause harm as they broke down the metal.
Some folks believe they can take BAL by mouth, but that route risks more than it helps. Swallowing dimercaprol can burn the throat, damage the stomach lining, or put the kidneys under pressure. Medical guidelines show that injections protect the gut from these irritations. With injections, caregivers can react if someone faints or has an allergic response, something not easy to catch on an outpatient visit.
People exposed to arsenic, mercury vapor, or certain pesticides may need more than just the chemical antidote—they need fluids, oxygen, sometimes even kidney support. One of my colleagues moved through dozens of patients during an industrial accident, pairing BAL with IV drips and even ventilators to calm the crisis. BAL isn’t a magic bullet; it works best when the patient’s care team acts fast and covers all the bases.
Few hospitals in rural areas keep BAL stocked. Shipping it from city pharmacies costs valuable time. Teaching paramedics and community clinics about dimercaprol has helped cut delays in some regions. Mobile medical teams carry it in their kits. Companies and governments could invest in better stock rotation and local training to close the urban-rural care gap.
Heavy metal poisoning hits hardest where regulations run thin: paint factories, battery plants, illegal mining sites. The antidote’s only half the story—prevention and education matter just as much as any injection. We need stricter oversight, safer workplaces, and regular testing. Fix the root, and there’s less need to scramble for the antidote.
Administering BAL means dealing with discomfort, watching for complications, and acting faster than poison spreads. I’ve seen the relief in families’ eyes after their loved one gets timely treatment. Making BAL accessible and keeping clinicians sharp on its use save real lives—all the more reason to keep the system honest and up to date.
Years ago, one of my professors in clinical chemistry told a story about mercury poisoning at a local metal shop. The antidote that saved the day wasn’t flashy or some futuristic therapy. It was an older compound with a mouthful of a name: 2,3-Dimercapto-1-propanol, also known as British Anti-Lewisite (BAL). This drug came out of wartime necessity. Chemists in Britain developed it to counteract the effects of chemical warfare agents, especially Lewisite (an arsenic-based blister agent). Legacy sometimes doesn’t age well, but the story of this drug is all about practicality and human need.
Lead, arsenic, mercury, and gold—these metals don’t belong in the body. Surrounded by toxic metals, critical enzymes grind to a halt, and organ systems suffer. The body on its own struggles to get rid of these poisons once they find their way into tissues. That’s when people turn to chemical tools like 2,3-Dimercapto-1-propanol.
This compound isn’t magic, but its structure does most of the heavy lifting. It carries two sulfur-containing groups known as thiols. These sulfur groups behave like eager hands during a game of chemical tag. Toxic metals have a strong attraction to sulfur, so the drug latches onto these metals tightly. The result looks a bit like clasping the metal in a chemical bear hug, forming stable complexes that free up proteins and enzymes in the body.
Chelation isn’t some high-concept science term only used in textbooks. People who work in labs or hospitals know it simply as “grabbing” metals. 2,3-Dimercapto-1-propanol’s two arms (the thiol groups) reach around the metal atom, forming what’s called a chelate ring. This wraps the toxic atom in a way that keeps it from doing more harm. Blood and kidneys then carry these new, safer complexes out to be passed in urine.
This kind of clean-up has saved many from the worst outcomes of acute poisoning. In my experience working with pediatricians worried about lead exposure, they kept a close eye on chelators. Even though newer drugs exist, nothing quite matches the grip BAL gives over certain metals, especially arsenic, gold, and in some cases, mercury.
Calling this drug a “cure-all” for heavy metal poisoning would be stretching the truth. The tight and fancy chemical corset it builds for the metals comes with its own downsides. 2,3-Dimercapto-1-propanol can sting when injected. It can trigger high blood pressure, kidney strain, or even allergic reactions, especially in people with a history of asthma. Clinicians have to weigh these risks against the threat posed by the metals themselves.
On top of that, not every metal responds the same. Iron and calcium ignore this drug, so cheat sheets don’t always help clinicians. BAL also struggles to reach metals that have already nestled deep into tissues.
Poisoning cases push medical teams to move fast and make decisions with limited information. Better detection and public awareness would cut down on many exposures before they turn into poisonings. Hospitals benefit from protocols that train staff to recognize and treat metal toxicity. Researchers continue designing new chelators that work better with fewer side effects.
Nothing replaces the effectiveness of quick intervention. But by learning from the old standbys, and not just reaching for the latest trend, we see just how powerful even the most straightforward chemical solutions can be when lives hang in the balance.
| Names | |
| Preferred IUPAC name | 2,3-bis(sulfanyl)propan-1-ol |
| Other names |
Dimercaprol British anti-Lewisite BAL 2,3-Dimercaptopropanol |
| Pronunciation | /ˌdaɪ.maɚˈkæp.toʊ.wʌnˈproʊ.pə.nɒl/ |
| Identifiers | |
| CAS Number | 59-52-9 |
| Beilstein Reference | 82264 |
| ChEBI | CHEBI:4446 |
| ChEMBL | CHEMBL1411 |
| ChemSpider | 5461 |
| DrugBank | DB00751 |
| ECHA InfoCard | 03bab7f8-d378-49ea-9589-9687336f179c |
| EC Number | 200-268-0 |
| Gmelin Reference | 123625 |
| KEGG | C06490 |
| MeSH | D008945 |
| PubChem CID | 6433322 |
| RTECS number | TE8750000 |
| UNII | WB9W5958P8 |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C3H8OS2 |
| Molar mass | 124.18 g/mol |
| Appearance | Colorless solid |
| Odor | mercaptan-like |
| Density | 1.295 g/cm³ |
| Solubility in water | soluble |
| log P | -0.62 |
| Vapor pressure | 0.00021 mmHg (25°C) |
| Acidity (pKa) | 9.7 |
| Basicity (pKb) | pKb = 11.5 |
| Magnetic susceptibility (χ) | -49.2·10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.570 |
| Viscosity | 52.3 cP (20°C) |
| Dipole moment | 2.18 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 122.3 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -125.7 kJ/mol |
| Pharmacology | |
| ATC code | V03AB03 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes skin and eye irritation, may cause allergic skin reaction. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS06,GHS08 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319 |
| Precautionary statements | P261, P280, P305+P351+P338, P337+P313 |
| Flash point | 85°C |
| Autoignition temperature | Autoignition temperature: 455°C (851°F) |
| Lethal dose or concentration | LD50 (oral, rat): 400 mg/kg |
| LD50 (median dose) | LD50 (median dose): Oral-rat LD50: 191 mg/kg |
| NIOSH | WN2450000 |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 0.1 ppm |
| IDLH (Immediate danger) | IDHL: 5 mg/m³ |
| Related compounds | |
| Related compounds |
Dithiol Ethylenediaminetetraacetic acid Dimercaprol DMSA DMPS |
